Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Busulphan lung in childhood

A Oakhill, I D Green, G T Knowlson

    Journal of Clinical Pathology
    |May 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.

    Nature communications·2021
    Same author

    Factors associated with ambulatory care sensitive emergency department visits for South Carolina Medicaid members with intellectual disability.

    Journal of intellectual disability research : JIDR·2017
    Same author

    Carboplatinum.

    Bristol medico-chirurgical journal (1963)·2017
    Same author

    Epirubicin.

    Bristol medico-chirurgical journal (1963)·2017
    Same author

    Ifosfamide ±VP16 in Childhood' Malignancy: A Phase II (toxicity) Study.

    Bristol medico-chirurgical journal (1963)·2017
    Same author

    De novo mutation causing sporadic type 2A von Willebrancd's disease: report of three cases.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016

    Busulphan is effective for chronic myeloid leukaemia but can cause lung complications. Regular pulmonary function tests are recommended to monitor for and manage busulphan lung.

    Area of Science:

    • Oncology
    • Pulmonology
    • Pharmacology

    Background:

    • Busulphan is a chemotherapy agent used for chronic myeloid leukaemia.
    • Long-term busulphan treatment can lead to serious adverse effects.
    • Early detection of complications is crucial for patient management.

    Observation:

    • A pediatric patient with chronic myeloid leukaemia showed initial positive response to busulphan.
    • After four years, the patient developed 'busulphan lung', a serious pulmonary complication.
    • Pulmonary function tests (PFT) were employed during monitoring.

    Findings:

    • Busulphan treatment, while effective, carries a risk of developing busulphan lung.
    • Pulmonary function tests demonstrated utility in tracking the progression of this condition.

    Related Experiment Videos

  • The case highlights a specific adverse event associated with prolonged busulphan use.

    • Implications:

    • Regular pulmonary function testing should be considered for patients undergoing long-term busulphan therapy.
    • This monitoring strategy may aid in the early identification and management of busulphan lung.
    • Further research into the mechanisms and prevention of busulphan lung is warranted.